Success Metrics

Active Trials

4(80%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Active, not recruiting3

Recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

active_not_recruiting360%

recruiting120%

withdrawn120%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

NCT06066203

active_not_recruitingphase_1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

NCT05160545

active_not_recruitingphase_1

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

NCT05944978

active_not_recruitingphase_1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

NCT05104775

withdrawnphase_1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05039931

Clinical Trials (5)

Showing 5 of 5 trials

NCT06066203Phase 1

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Recruiting

NCT05160545Phase 1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Active Not Recruiting

NCT05944978Phase 1

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Active Not Recruiting

NCT05104775Phase 1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Active Not Recruiting

NCT05039931Phase 1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5